ArticleChemMedChem2017
Potent Pyrimidine and Pyrrolopyrimidine Inhibitors of Testis-Specific Serine/Threonine Kinase 2 (TSSK2).
Article in ChemMedChem, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Development of TSSK1 and TSSK2 Targeted Degraders Reveals Sperm Machinery for Protein Degradation and Potential for Nonhormonal Male Contraception.Journal of medicinal chemistry · 2026Article
- TSSKL is essential for sperm mitochondrial morphogenesis and male fertility in moths.PLoS genetics · 2025Article
- Identification of TSSK1 and TSSK2 as Novel Targets for Male Contraception.Biomolecules · 2025Article
- Article
- Male contraception: narrative review of ongoing research.Basic and clinical andrology · 2023Review
- Various gene modification techniques to discover molecular targets for nonhormonal male contraceptives: A review.International journal of reproductive biomedicine · 2023Review
- The novel BRDT inhibitor NHWD870 shows potential as a male contraceptive in mice.Acta biochimica et biophysica Sinica · 2022Article
- Role of testis‑specific serine kinase 1B in undiagnosed male infertility.Molecular medicine reports · 2022Article
- TSSK3, a novel target for male contraception, is required for spermiogenesis.Molecular reproduction and development · 2021Article
- Update on Novel Hormonal and Nonhormonal Male Contraceptive Development.The Journal of clinical endocrinology and metabolism · 2021Review
- PKIS deep dive yields a chemical starting point for dark kinases and a cell active BRSK2 inhibitor.Scientific reports · 2020Article
- Testis-specific serine kinase protein family in male fertility and as targets for non-hormonal male contraception†.Biology of reproduction · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Testis-specific serine/threonine kinase 2 (TSSK2) is an important target for reversible male contraception. A high-throughput screen of ≈17 000 compounds using a mobility shift assay identified two potent series of inhibitors having a pyrrolopyrimidine or pyrimidine core. The pyrrolopyrimidine 10 (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.